CtrlK
TECH
NASDAQ
Life Sciences Tools & Services
$72.12
USD
+$0.35 (+0.49%)
At close: Jul 17, 2026, 4:00 PM EDT
Market Cap:
$11.24B
Volume:
3.1M
Previous Close
$71.77
Day Range
$71.50 - $72.12
52 Week Range
$43.20 - $72.16
Average Volume (10 Days)
4.5M
P/E Ratio (TTM)
103.68
Dividend Yield
0.44%
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
CEO
Mr. Kim Kelderman
Headquaters
Minneapolis, MINNESOTA, US
Founded
1989
Employees
3,100
German pharmaceutical giant Merck KGaA announced an $11.3 billion acquisition of Minnesota-based Bio-Techne, its largest deal in over a decade. The purchase strengthens Merck's foothold in life sciences tools used for drug discovery and gene therapy, while Bio-Techne shareholders see immediate gains after years of underperformance.
0
0
Germany's Merck KGaA announced a definitive agreement to acquire Bio-Techne for $73 per share in cash, representing a 24% premium and an enterprise value of $11.3 billion. The deal adds Bio-Techne's portfolio of reagents, antibodies, and bioprocessing tools to Merck's Life Science business, with expected annual cost savings of approximately 140 million euros by year three.
0
0
